- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06459635
Migraine-aanval Pijnfasevoorspellingsonderzoek (PREDI-CRISIS)
Voorspellingsstudie van de pijnfase van migraineaanvallen bij patiënten met episodische migraine
The study of the ability to predict pain in a migraine attack, through premonitory symptoms and through an ambulatory monitoring device through real-time recording of hemodynamic variables, is one of the strategic lines of research of the unit. of Headaches at the Hospital de La Princesa since 2013 together with the Complutense and Polytechnic University of Madrid. Their results have been reflected in various publications (Pagán J, et al. Sensors 2015; Gago-Veiga AB, et al. J Pain Res 2018) and have promoted the creation of several invention patents.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
Patients with episodic migraine will be recruited from the monographic headache clinics of the 7 centers participating in the study. These patients, for a maximum period of 2 months, must monitor their hemodynamic variables with a wearable device and record all the clinical characteristics of their migraine attacks. Subsequently, with these records, an individualized algorithm will be created for each patient that aims to predict the onset of the migraine attack.
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
Madrid
-
Madrid, Madrid, Spanje, 28006
- Hospital Universitario de La Princesa
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Patients aged between 18 and 65 years with a diagnosis of episodic migraine who have between 4 and 14 days of headache per month. These patients will come from 7 Headache Units in Spain belonging to the following hospitals: • La Princesa University Hospital • Vall 'Hebron University Hospital • Marqués de Valdecilla University Hospital • Valladolid University Clinical Hospital • Donostia University Hospital • Lozano Blesa University Clinical Hospital • La Fe Polytechnic University Hospital
Beschrijving
Inclusion Criteria:
- Age between 15 years and 69 years.
- Diagnosed with migraine by a headache neurologist and according to the criteria proposed by ICHD-3.
- History of migraine of at least 1 year of evolution.
- Normal neurological examination.
- Have given your informed consent.
- Be able to describe your clinical situation and the characteristics of your headache.
- Have an average of 10 to 14 migraine days per month in the three months prior to inclusion (high-frequency episodic migraine).
- User-level management capacity of "smartphone" type electronic devices.
- Be able to complete two months of study follow-up.
Exclusion Criteria:
- Presence of another type of headache, with the exception of headache due to excessive use of analgesic medication.
- Cognitive deficiency or any other pathology that may prevent or make it difficult for the patient to perform the study correctly.
- Neurological focus in the examination.
- Pregnancy or breastfeeding period.
- Patients with known heart disease or bronchopathy, Sjögren's syndrome, diabetes mellitus, or hypo/hyperthyroidism.
- Carriers of pacemakers, neurostimulators or any other electronic device that is considered to make the interpretation of biometric records difficult.
- Anatomical problem that makes the use of the device impossible.
- Patients in whom it is expected that a change in migraine preventive treatment or other usual treatment will be possible during the study period.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: CASE_CONTROL
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
|---|
|
Patients with episodic migraine
Patients with episodic migraine who present between 4 and 10 migraine attacks per month. These patients must have a diagnosis of migraine by a headache neurologist and according to the criteria proposed by ICHD-3. In addition, they must present at least 1 year of evolution of the migraine, as well as a normal neurological examination and have given their informed consent. |
|
Control patients
People who have never had a headache episode with migraine characteristics. These may present, at most, one episode per month of headache with non-migraine characteristics in the last 3 months. In turn, they should not have a family history of migraine (1st and 2nd degree). |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Development of a prediction strategy for the onset of migraine
Tijdsspanne: From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
Develop a prediction strategy for the onset of migraine attacks in patients with episodic migraine, based on hemodynamic and clinical variables of migraine attacks. |
From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Posibility of predict the onset of pain in a migraine attack
Tijdsspanne: From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
To analyze whether it is possible to predict the onset of pain in a migraine attack, through ambulatory and non-invasive monitoring of physiological variables. |
From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
|
Individualized prediction algorithm
Tijdsspanne: From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
Implement an individualized prediction algorithm that allows real-time prediction of the symptomatic phase of the migraine attack. |
From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
|
Effectiveness of the prediction model
Tijdsspanne: From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
Measure the effectiveness of the prediction model both at the individual level and in a large group of patients. |
From the beginning of treatment, which is the initial visit, to 2 months of follow-up
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Ana Beatriz Gago Veiga, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Publicaties en nuttige links
Algemene publicaties
- Gago-Veiga AB, Pagan J, Henares K, Heredia P, Gonzalez-Garcia N, De Orbe MI, Ayala JL, Sobrado M, Vivancos J. To what extent are patients with migraine able to predict attacks? J Pain Res. 2018 Sep 27;11:2083-2094. doi: 10.2147/JPR.S175602. eCollection 2018.
- Pagan J, De Orbe MI, Gago A, Sobrado M, Risco-Martin JL, Mora JV, Moya JM, Ayala JL. Robust and Accurate Modeling Approaches for Migraine Per-Patient Prediction from Ambulatory Data. Sensors (Basel). 2015 Jun 30;15(7):15419-42. doi: 10.3390/s150715419.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Pijn
- Neurologische manifestaties
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Hoofdpijnaandoeningen, primair
- Hoofdpijn aandoeningen
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Migraine-stoornissen
- Hoofdpijn
- Migraine met Aura
- Migraine zonder Aura
Andere studie-ID-nummers
- 3513
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Individual participant data (IPD) will not be shared with other researchers. This decision is based on data protection and confidentiality requirements in accordance with applicable European and national regulations (including GDPR). Given that this is a multicentre observational study conducted in routine clinical practice, access to IPD is restricted to the study investigators for the purposes of the predefined analyses.
Any potential secondary use of the dataset would only be considered in fully anonymized form and subject to prior ethical approval and compliance with applicable data protection legislation.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .